Literature DB >> 25514871

Epidermal growth factor receptor variant III renders glioma cancer cells less differentiated by JAGGED1.

Eun-Jung Kim1, Sung-Ok Kim, Xiong Jin, Seok Won Ham, Jaebong Kim, Jae-Bong Park, Jae-Yong Lee, Sung-Chan Kim, Hyunggee Kim.   

Abstract

Glioblastoma is a highly aggressive primary brain tumor in which the majority of cancer cells are undifferentiated. One of the most common oncogenic drivers for this malignancy is the epidermal growth factor receptor variant III (EGFRvIII), which lacks a portion of the extracellular ligand-binding domain due to deletion of exons 2-7 of the EGFR gene. EGFRvIII plays a critical role in tumor progression, promoting acquisition of stem cell-like features including an undifferentiated state and therapy resistance. However, the molecular mechanisms by which EGFRvIII contributes to cancer cell aggressiveness remain poorly understood. Here, we show that EGFR expression correlates with JAGGED1 expression in glioblastoma patients. Overexpression of EGFRvIII in glioma cell lines augmented JAGGED1 expression at the transcriptional level through the mitogen-activated protein kinase signaling pathway. Consequently, EGFRvIII overexpression drove partial dedifferentiation of glioma cells, as determined by tumorsphere-forming ability and expression of stem cell markers, through JAGGED1 induction. EGFRvIII-mediated radioresistance, but not chemoresistance, was also modulated by JAGGED1. Taken together, our results provide new insight into the mechanism underlying EGFRvIII-driven glioblastoma aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25514871     DOI: 10.1007/s13277-014-2922-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

Review 1.  Glioblastoma cancer stem cells--from concept to clinical application.

Authors:  Barbara E Stopschinski; Christoph P Beier; Dagmar Beier
Journal:  Cancer Lett       Date:  2012-06-02       Impact factor: 8.679

2.  Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.

Authors:  Khatri Latha; Ming Li; Vaibhav Chumbalkar; Anupama Gururaj; YeoHyeon Hwang; Sumana Dakeng; Raymond Sawaya; Kenneth Aldape; Webster K Cavenee; Oliver Bogler; Frank B Furnari
Journal:  Int J Cancer       Date:  2012-07-09       Impact factor: 7.396

3.  Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair.

Authors:  Mahmoud Toulany; Kyung-Jong Lee; Kazi R Fattah; Yu-Fen Lin; Brigit Fehrenbacher; Martin Schaller; Benjamin P Chen; David J Chen; H Peter Rodemann
Journal:  Mol Cancer Res       Date:  2012-05-17       Impact factor: 5.852

4.  Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling.

Authors:  Qinghua Zeng; Shenglin Li; Douglas B Chepeha; Thomas J Giordano; Jong Li; Honglai Zhang; Peter J Polverini; Jacques Nor; Jan Kitajewski; Cun-Yu Wang
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

5.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

6.  EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction.

Authors:  Xun Jin; Jinlong Yin; Sung-Hak Kim; Young-Woo Sohn; Samuel Beck; Young Chang Lim; Do-Hyun Nam; Yun-Jaie Choi; Hyunggee Kim
Journal:  Cancer Res       Date:  2011-10-05       Impact factor: 12.701

7.  Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling.

Authors:  Hye-Min Jeon; Xun Jin; Joong-Seob Lee; Se-Yeong Oh; Young-Woo Sohn; Hyo-Jung Park; Kyeung Min Joo; Woong-Yang Park; Do-Hyun Nam; Ronald A DePinho; Lynda Chin; Hyunggee Kim
Journal:  Genes Dev       Date:  2008-08-01       Impact factor: 11.361

8.  Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression.

Authors:  Hye-Min Jeon; Sung-Hak Kim; Xun Jin; Jong Bae Park; Se Hoon Kim; Kaushal Joshi; Ichiro Nakano; Hyunggee Kim
Journal:  Cancer Res       Date:  2014-06-24       Impact factor: 12.701

9.  Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells.

Authors:  Angel Ayuso-Sacido; Jennifer A Moliterno; Sebila Kratovac; Gurpreet S Kapoor; Donald M O'Rourke; Eric C Holland; Jose Manuel García-Verdugo; Neeta S Roy; John A Boockvar
Journal:  J Neurooncol       Date:  2009-10-24       Impact factor: 4.130

Review 10.  Molecular culprits generating brain tumor stem cells.

Authors:  Se-Yeong Oh; Hyunggee Kim
Journal:  Brain Tumor Res Treat       Date:  2013-04-30
View more
  4 in total

Review 1.  EGFR Amplification and Glioblastoma Stem-Like Cells.

Authors:  Katrin Liffers; Katrin Lamszus; Alexander Schulte
Journal:  Stem Cells Int       Date:  2015-06-02       Impact factor: 5.443

2.  Effects of combined radiosurgery and temozolomide therapy on epidermal growth factor receptor and variant III in glioblastoma multiforme.

Authors:  Yiguang Lin; Junhu Zhou; Jianglong Xu; Kai Zhao; Xiaomin Liu; Guokai Wang; Zhiyuan Zhang; Youlin Ge; Yongqing Zong; Desheng Xu; Yanli Tan; Chuan Fang; Chunsheng Kang
Journal:  Oncol Lett       Date:  2018-02-14       Impact factor: 2.967

3.  Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.

Authors:  Raghupathy Vengoji; Muzafar A Macha; Rama Krishna Nimmakayala; Satyanarayana Rachagani; Jawed A Siddiqui; Kavita Mallya; Santhi Gorantla; Maneesh Jain; Moorthy P Ponnusamy; Surinder K Batra; Nicole Shonka
Journal:  J Exp Clin Cancer Res       Date:  2019-06-18

Review 4.  Radioresistance of Brain Tumors.

Authors:  Kevin Kelley; Jonathan Knisely; Marc Symons; Rosamaria Ruggieri
Journal:  Cancers (Basel)       Date:  2016-03-30       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.